Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention and Treatment of Interstitial Lung Disease in Systemic Sclerosis

NCT01858259 is registered in ClinicalTrials.gov with Gabriela Riemekasten as lead sponsor.

NCT NCT01858259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01858259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention and Treatment of Interstitial Lung Disease in Systemic Sclerosis
Lead sponsor
Gabriela Riemekasten
Phase
Observational
Overall status
Unknown status
Start date
May 31, 2013
Completion date
June 30, 2016
Enrollment
1,372 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung diseases, systemic sclerosis